44 results
SC TO-T/A
Swedish Orphpan Biovitrum AB
13 Jun 23
Third party tender offer statement (amended)
7:01am
paragraph immediately after the last paragraph of such subsection with the caption “Antitrust Compliance – HSR Act:”
“Each of CTI BioPharma and Sobi filed … a Premerger Notification and Report Form under the HSR Act with the FTC and the Antitrust Division in connection with the purchase of Shares
SC 14D9/A
CTIC
CTI BioPharma Corp
12 Jun 23
Tender offer solicitation (amended)
6:06am
“Regulatory Approvals—Antitrust in the United States”:
“Under the HSR Act, the purchase of Shares in the Offer may not be completed until the expiration … and the Merger with the FTC and the Antitrust Division, unless the waiting period is earlier terminated by the FTC and the Antitrust Division. If the 15th
SC 14D9
CTIC
CTI BioPharma Corp
25 May 23
Tender offer solicitation
7:00am
-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”); and (iv) those other conditions set forth in Annex I to the Merger Agreement … (and any extension thereof) applicable to the consummation of the Offer under the HSR Act or any foreign antitrust or competition-related legal
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
waiting period applicable to the Offer under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended. The Offer is also subject
SC TO-T
EX-99
CTIC
CTI BioPharma Corp
25 May 23
Third party tender offer statement
6:46am
a majority of the total number of CTI’s outstanding shares of common stock and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Sobi
SC TO-T
EX-99
d0hw7t6v1t l59x
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
ah8p5u95oewnl
25 May 23
Third party tender offer statement
6:46am
SC TO-T
EX-99
651w9rlwaowkqvh
25 May 23
Third party tender offer statement
6:46am
SC TO-C
EX-99.1
kof4d7dvj
10 May 23
Information about tender offer
5:01pm
SC14D9C
EX-99.2
qo9fcldisqa96d
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
4yic43 0xz1a0nh
10 May 23
Written communication relating to third party tender offer
1:30pm
SC14D9C
EX-2.1
pyi ev12r
10 May 23
Written communication relating to third party tender offer
1:30pm
8-K
EX-99.2
xzyb23p
10 May 23
Tender and Support Agreement
8:05am
8-K
oi7wdyw
10 May 23
Tender and Support Agreement
8:05am
8-K
EX-2.1
hw0rq561nqpdl
10 May 23
Tender and Support Agreement
8:05am
8-K
exgh8
22 Mar 11
Other Events
12:00am
8-K
7vz occq07
14 Mar 11
Phase III Pivotal Trial in Acute Myeloid Leukemia Expected to Start in Q4 2011
12:00am
8-K
EX-99.1
u5w8frfr8y d6cr67s
30 Sep 09
Regulation FD Disclosure
12:00am